tripegfilgrastim
Recombinant proteinexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 10, 2023 (NCT06135896)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Granulocyte colony stimulating factor receptorSupplementation
CSF3R supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06135896 | Phase 2 | Dec 10, 2023 | National Cancer Center, Korea, Seoul National University, The National Cancer Center |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Center, Korea | Government | 1 | 1 | 1 | 2023 |
| Seoul National University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| The National Cancer Center | Academic/Hospital | 1 | 0 | 1 | 2023 |
3 organizations
Page 1 / 1